Top Markets
Coin of the day
Baudax Bio, Inc. Baudax Bio, Inc.

Baudax Bio, Inc.

BXRXQ
Rangering i aksjer #42133
Baudax Bio, Inc., a biotechnology company, develops and commercializes products... Baudax Bio, Inc., a biotechnology company, develops and commercializes products for hospital and other acute care related settings. The company develops T cell receptor, that focus on immune modulating therapies for orphan diseases or complications associated with such diseases, as well as the treatment of autoimmune disorders. It also develops BX1000, an intermediate-acting neuromuscular blocking agent (NMB) that is in phase II clinical trial; BX2000, an ultra- short acting NMB, which is in phase I clinical trial, as well as a proprietary blockade reversal agent; and BX3000, a NMB reversal agent that is in preclinical studies. Baudax Bio, Inc. was incorporated in 2015 and is based in Malvern, Pennsylvania. On February 22, 2024, Baudax Bio, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Eastern District of Pennsylvania.
Aksjekurs
$0.0001
Sist synkronisert: 2026-08-11
Markedsverdi
$4.36K
Endring (1 dag)
0.00%
Endring (1 år)
9,900.00%
Land
US
Handel Baudax Bio, Inc. (BXRXQ)

Kategori

Inntekter for Baudax Bio, Inc. (BXRXQ)
Inntekter i 2026 TTM: 0
Ifølge Baudax Bio, Inc. sine nyeste økonomiske rapporter er selskapets nåværende resultat 0. I 2026 hadde selskapet et resultat på 0, lik resultatet i 2026, som var 0. Resultatet som vises på denne siden er resultat før renter og skatt, eller EBIT.
Inntektshistorikk for Baudax Bio, Inc. fra 2026 til 2026
Inntekter ved slutten av hvert år
År Inntekter Endre
Ikke nok data for de angitte datoene.
Inntekter for lignende selskaper eller konkurrenter
Selskap Inntekter Forskjell i inntekter Land
$5.27B -
US
$1.95B -
NL
- -
CH
$3.01B -
BE
- -
KR